Kyntra Bio (NASDAQ:KYNB – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Kyntra Bio and VistaGen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 3 | 0 | 2.40 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
Kyntra Bio currently has a consensus price target of $36.00, suggesting a potential upside of 347.76%. VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 295.83%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Kyntra Bio is more favorable than VistaGen Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
Earnings and Valuation
This table compares Kyntra Bio and VistaGen Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyntra Bio | $6.44 million | 5.06 | $183.45 million | $45.30 | 0.18 |
| VistaGen Therapeutics | $1.27 million | 8.39 | -$69.68 million | ($1.66) | -0.14 |
Kyntra Bio has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Kyntra Bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Summary
Kyntra Bio beats VistaGen Therapeutics on 12 of the 14 factors compared between the two stocks.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
